TrivarX Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	1.5yrs
Durée moyenne du mandat des membres du conseil d'administration	2.7yrs

Mises à jour récentes de la gestion

Recent updates

PDG

TrivarX n'a pas de PDG, ou nous n'avons pas de données sur eux.

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Kai Sun	Chief Operating Officer	1.3yrs	AU$173.73k	0.40% A$ 29.3k
Josh Purdy	Public Relations Director	no data	pas de données	pas de données
Archie Defillo	Chief Medical Officer	no data	pas de données	pas de données
Massimiliano Grassi	Head of Artificial Intelligence	4.8yrs	pas de données	pas de données
Anthony Keating	Executive Director	less than a year	pas de données	0.24% A$ 17.6k
Stephen Buckley	Company Secretary	1.6yrs	pas de données	pas de données

1.5yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de TRI n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Anthony Keating	Executive Director	less than a year	pas de données	0.24% A$ 17.6k
Christopher Ntoumenopoulos	Independent Non-Executive Director	1.8yrs	AU$79.79k	1.33% A$ 97.0k
Peter Carlisle	Chairman of Growth & Advocacy Advisory Board	7.4yrs	AU$48.02k	pas de données
Patrick Kennedy	Member of Growth & Advocacy Advisory Board	5.3yrs	pas de données	pas de données
John Mathias	Independent Non-Executive Director	less than a year	pas de données	pas de données
Michael Phelps	Member of Growth & Advocacy Advisory Board	5.3yrs	pas de données	pas de données
David Trimboli	Independent Non-Executive Chairman	2.3yrs	AU$97.44k	pas de données
Elizabeth Lombardo	Member of Growth & Advocacy Advisory Board	3.2yrs	pas de données	pas de données

2.7yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Le conseil d'administration de la TRI n'est pas considéré comme expérimenté ( 2.7 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

TrivarX Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

Medibio Limited, Annual General Meeting, Nov 29, 2023

Medibio Limited, Annual General Meeting, Oct 06, 2023

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Recent updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

PDG

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi